Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) saw a significant decrease in short interest during the month of September. As of September 30th, there was short interest totalling 1,040,000 shares, a decrease of 7.1% from the September 15th total of 1,120,000 shares. Currently, 3.4% of the company’s stock are sold short. Based on an average trading volume of 184,400 shares, the short-interest ratio is presently 5.6 days.
Werewolf Therapeutics Trading Down 0.5 %
NASDAQ:HOWL opened at $2.05 on Friday. The company has a market capitalization of $89.08 million, a P/E ratio of -1.88 and a beta of 0.45. The company has a current ratio of 12.13, a quick ratio of 12.13 and a debt-to-equity ratio of 0.24. Werewolf Therapeutics has a 12 month low of $1.57 and a 12 month high of $8.19. The firm has a fifty day simple moving average of $2.11 and a 200-day simple moving average of $3.37.
Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 48.25%. The firm had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $2.00 million. On average, equities research analysts anticipate that Werewolf Therapeutics will post -1.64 earnings per share for the current year.
Hedge Funds Weigh In On Werewolf Therapeutics
Analyst Upgrades and Downgrades
Several equities analysts have issued reports on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $12.00 price target on shares of Werewolf Therapeutics in a research report on Wednesday, June 26th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Werewolf Therapeutics in a research report on Tuesday, July 2nd.
View Our Latest Report on HOWL
About Werewolf Therapeutics
Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
Read More
- Five stocks we like better than Werewolf Therapeutics
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- Stock Splits, Do They Really Impact Investors?
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- 5 Top Rated Dividend Stocks to Consider
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.